REGIONAL CANCER CARE ASSOCIATES

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2023–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	1	1
2025	—	4	1
2024	—	4	1
2023	—	4	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
ARNOLD & PORTER KAYE SCHOLER LLP	—	13

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	7
SENATE	7
Centers For Medicare and Medicaid Services (CMS)	2
Health & Human Services, Dept of (HHS)	2

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medicare/Medicaid	Medicare/Medicaid	8

Bills Explicitly Cited (7)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2484119th Congress

Seniors’ Access to Critical Medications Act of 2025

2025 · first_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursement of certain oncology drugs. Issues related to the Seniors Access to Critical Medications Act of 2025 (H.R. 2484).

Client expense: — · Firm income: —

Matched citations: H.R. 2484

H.R. 5526118th Congress

Seniors’ Access to Critical Medications Act of 2024

2024 · fourth_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursement of certain oncology drugs. Issues related to the Seniors Access to Critical Medications Act of 2023 (H.R. 5526 / S. 3458, 118th Congress).

Client expense: — · Firm income: —

Matched citations: H.R. 5526

S. 3458118th Congress

Seniors’ Access to Critical Medications Act of 2023

2024 · fourth_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursement of certain oncology drugs. Issues related to the Seniors Access to Critical Medications Act of 2023 (H.R. 5526 / S. 3458, 118th Congress).

Client expense: — · Firm income: —

Matched citations: S. 3458

H.R. 5526118th Congress

Seniors’ Access to Critical Medications Act of 2024

2024 · second_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursement of certain oncology drugs. Issues related to the Seniors Access to Critical Medications Act of 2023 (H.R. 5526 / S. 3458).

Client expense: — · Firm income: —

Matched citations: H.R. 5526

Show 3 more cited filings

S. 3458118th Congress

Seniors’ Access to Critical Medications Act of 2023

2024 · second_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursement of certain oncology drugs. Issues related to the Seniors Access to Critical Medications Act of 2023 (H.R. 5526 / S. 3458).

Client expense: — · Firm income: —

Matched citations: S. 3458

H.R. 5526118th Congress

Seniors’ Access to Critical Medications Act of 2024

2024 · first_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursement of certain oncology drugs. Issues related to the Seniors Access to Critical Medications Act of 2023 (H.R. 5526).

Client expense: — · Firm income: —

Matched citations: H.R. 5526

H.R. 5526118th Congress

Seniors’ Access to Critical Medications Act of 2024

2023 · fourth_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursement of certain oncology drugs. Issues related to the Seniors Access to Critical Medications Act of 2023 (H.R. 5526).

Client expense: — · Firm income: $10,000

Matched citations: H.R. 5526

Source: Senate LDA

REGIONAL CANCER CARE ASSOCIATES — Lobbying Disclosure | Poliscope